ProteoNic is a biotechnology company active in development and licensing of DNA technology for cell line generation and recombinant protein production for pharmaceutical applications. We offer premium vector technology that substantially boosts production levels of therapeutic proteins and other biologics. Cost savings are immediate and sizeable, freeing up production capacity and enabling commercially viable production of difficult to express proteins.ProteoNic’s 2G UNic™ drives higher production for all types of therapeutic protein products, including monoclonal antibodies, biosimilars and more difficult-to-express (DTE) proteins, such as Fc-fusion proteins and bi-specifics, contributing to their economic viability. Our patented technology does not require modifications to existing production systems or work flows and is compatible with all production cell lines and expression systems used in the industry. Independent technical and commercial validation by third parties, including top tier biopharma, demonstrates severalfold productivity level increases that translate into multi-million Euros in annual cost savings.

 Agilent Technologies Inc. today announced that the South Korea Ministry of Food and Drug Safety has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify patients with non-small cell lung cancer who are suitable for first-line monotherapy with KEYTRUDA (pembrolizumab) on the Dako Omnis platform.

 Pfizer Inc. and BioNTech SE today announced the European Medicines Agency has initiated a rolling review for a variant-adapted version of the companies’ COVID-19 vaccine. This rolling review is initially based on chemistry, manufacturing, and controls data shared with EMA earlier this month. As clinical data become available, including data on immunogenicity against Omicron and its subvariants, it will be added to the rolling submission. 

Shionogi & Co., Ltd. and the Global Antibiotic Research and Development Partnership have today announced the execution of a license and technology transfer agreement and, with the Clinton Health Access Initiative , a collaboration agreement that aim to significantly transform the landscape of access to antibiotics for countries around the world.

Horizon Therapeutics plc today announced that it has submitted a regulatory filing to the Brazil National Health Surveillance Agency for UPLIZNA for the treatment of adult patients with anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD).